Oppenheimer downgraded Bioceres (BIOX) to Perform from Outperform without a price target The firm believes the company’s portfolio recapitalization “now appears incrementally challenging.” Bioceres is seeing pressure amid Argentina liquidity concerns, and the notice of default from one its largest stakeholders “creates a significant impediment to our portfolio transformation thesis,” the analyst tells investors in a research note. Oppenheimer cites Argentina volatility for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres Crop Solutions Faces Board Resignation Amid Financial Dispute
- Bioceres, Colorado Wheat Research Foundation team on HB4 wheat commercialization
- Bioceres price target lowered to $5 from $8 at Lake Street
- Bioceres downgraded to Hold from Buy at Canaccord
- Bioceres Crop Solutions: Hold Rating Amid Macroeconomic Challenges and Strategic Shift